CTOs on the Move

Dicerna

www.dicerna.com

 
Dicerna is working to improve the lives of people suffering from rare diseases, chronic liver diseases, cardiovascular disease, and viral liver infectious diseases. We discover and develop innovative therapies to stop or turn off destructive disease processes by silencing the genes underlying these processes. Our proprietary, next-generation technology, GalXC™, is a platform that uses the body`s natural biological pathways to silence genes in the liver with a high degree of selectivity and specificity. By targeting genes that contribute to serious diseases, we seek to address the underlying cause of illness and restore health. We have qualified dozens of disease-associated genes ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.dicerna.com
  • 33 Hayden Avenue
    Lexington, MA USA 02421
  • Phone: 617.621.8097

Executives

Name Title Contact Details

Funding

Dicerna raised $70M on 03/30/2017
Dicerna raised $100M on 10/29/2018

Similar Companies

Rayner

This is an example page. It’s different from a blog post because it will stay in one place and will show up in your site navigation (in most themes). Most people start with an About page that introduces them to potential site visitors. It might say som...

Everett Laboratories Inc

Everett Laboratories Inc is a West Orange, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Nexelis, a Q² Solutions

On the Forefront of COVID-19 Recognized leader in the COVID-19 field by governmental and non-governmental organizations as the reference assay...

Jamol Laboratories

Jamol Laboratories is a Emerson, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Precision Medicine Group

We founded Precision Medicine Group in 2012 because we believed there was a transformational opportunity to improve the process of bringing new drugs to market. It involves utilizing technology, data, and human expertise. It is a big challenge that requires diverse talents. Our model involves both nurturing and investing organically and acquiring capabilities that we do not have but critically need. Our core executive team is anchored to this model, building life science services that address fundamental changes in healthcare that are necessary for health and outcomes improvement.